Health Catalyst, Inc. HCAT R2KPHARMA
Company Overview
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. The company operates in two segments: Technology and Professional Services. It offers ignite data and analytics platform that provides clients a single comprehensive environment to integrate and organize data from their disparate software systems; and applications, a software analytics applications build for ignite platform to analyze clients face across clinical improvement, revenue and cost improvement, ambulatory operations, measures and registries, and data and analytics. The company also provides expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. It serves academic medical centers, integrated delivery networks, community hospitals, large physician practices, accountable care organizations, health information exchanges, health insurers, life science organizations, healthcare technology vendors, and other risk-bearing entities. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
Why Investors Should Care
Revenue has grown at a 19.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $311.14M (+1.5% YoY); net profit $-177.97M.
- Trailing 12 Months Year-on-year growth — revenue -12.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.85% |
| 1 Year: | -12.70% |
Stock Price Performance
| 1 Year: | -47.52% |
| 6 Months: | +22.46% |
| 3 Months: | -21.40% |
| 1 Month: | -2.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross9d ago
- RSI (14)43.08 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 19.9% over 5 years.
CONS
- Trading 54.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HCAT Health Catalyst, Inc. R2KPHARMA | 1.69 | -0.46 | $127.18M | 0.00% | -38.94% | -118.12% | 19.85% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.99M | 32.87M | 35.21M | 36.80M | 39.42M | 45.12M | 43.26M | 47.19M | 55.85M | 59.63M | 61.74M | 68.09M | 70.63M | 68.35M | 73.87M | 73.21M | 73.77M | 74.72M | 75.90M | 76.35M | 79.41M | 80.72M | 76.32M | 70.76M | 70.49M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.29M | - | - | 40.13M | - | - |
| Operating Income | -18.81M | -16.50M | -11.09M | -9.36M | -20.74M | -18.11M | -15.64M | -23.46M | -24.32M | -32.32M | -42.25M | -24.35M | -33.19M | -45.72M | -34.91M | -34.62M | -24.58M | -22.81M | -15.81M | -13.69M | -20.17M | -37.09M | -17.51M | -106.48M | -36.48M |
| Net Income | -19.32M | -16.88M | -13.72M | -10.69M | -21.42M | -17.49M | -27.18M | -27.33M | -28.37M | -35.83M | -40.01M | -22.46M | -33.43M | -45.73M | -33.19M | -32.61M | -22.03M | -20.59M | -13.52M | -14.73M | -23.74M | -40.98M | -22.23M | -111.03M | -40.54M |
| Diluted EPS | - | - | - | - | - | -0.47 | -0.71 | -0.68 | -0.65 | -0.80 | -0.82 | -0.54 | -0.62 | -0.84 | -0.60 | -0.58 | -0.39 | -0.35 | -0.23 | -0.24 | -0.35 | -0.59 | -0.32 | -1.53 | -0.55 |
| R&D Expense | 8.49M | 10.84M | 10.02M | 9.71M | 13.48M | 13.09M | 12.06M | 13.39M | 14.35M | 14.52M | 16.39M | 17.15M | 18.15M | 20.77M | 17.08M | 17.59M | 17.67M | 14.87M | 13.88M | 14.19M | 15.19M | 12.39M | 12.28M | 9.78M | 11.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 73.08M | 112.57M | 154.94M | 188.84M | 241.93M | 276.24M | 295.94M | 306.58M | 311.14M |
| Operating Income | -45.54M | -60.09M | -54.87M | -96.12M | -143.65M | -140.00M | -126.90M | -69.81M | -160.85M |
| Net Income | -47.03M | -61.98M | -60.10M | -115.02M | -153.21M | -137.40M | -118.15M | -69.50M | -177.97M |
| Diluted EPS | - | - | -12.86 | -2.91 | -3.23 | -2.63 | -2.09 | -1.15 | -2.55 |
| R&D Expense | 28.47M | 38.59M | 46.25M | 53.52M | 62.73M | 75.68M | 72.63M | 57.95M | 49.77M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 110.97M | 302.36M | 577.74M | 832.10M | 752.29M | 701.81M | 858.93M | 502.64M |
| Total Equity | -206.41M | -259.48M | -374.77M | 200.64M | 276.10M | 522.10M | 425.01M | 366.92M | 365.21M | 245.78M |
| Cash & Equivalents | - | - | 28.43M | 18.03M | 91.95M | 193.23M | 116.31M | 106.28M | 249.65M | 50.81M |
| Long Term Debt | - | - | 18.81M | 48.20M | 168.99M | 180.94M | 226.52M | 228.03M | 151.18M | 151.62M |
| Total Liabilities | - | - | 75.90M | 101.72M | 301.64M | 310.00M | 327.28M | 334.89M | 493.72M | 256.86M |
| Current Liabilities | - | - | 41.81M | 48.22M | 88.04M | 93.05M | 82.51M | 89.03M | 325.85M | 89.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.83M | -40.30M | -32.18M | -26.15M | -23.12M | -35.27M | -33.08M | 14.56M | 731.00K |
| Investing Cash Flow | 22.41M | 21.40M | -209.60M | -82.56M | -139.68M | -39.02M | 20.29M | -22.90M | 36.19M |
| Financing Cash Flow | 24.87M | 24.35M | 231.38M | 182.61M | 264.08M | -2.61M | 2.73M | 151.75M | -235.78M |
| Capital Expenditure | -2.47M | -2.08M | -2.02M | -7.78M | -10.45M | -2.17M | -1.24M | -1.62M | -968.00K |
| Free Cash Flow | -39.30M | -42.37M | -34.20M | -33.92M | -33.57M | -37.44M | -34.32M | 12.94M | -237.00K |
| Share Buybacks | 0 | 8.71M | 0 | 0 | 0 | 8.39M | 1.81M | 0 | 5.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -62.3% | -53.4% | -35.4% | -50.9% | -59.4% | -50.7% | -42.9% | -22.8% | -51.7% |
| Net Margin % | -64.4% | -55.1% | -38.8% | -60.9% | -63.3% | -49.7% | -39.9% | -22.7% | -57.2% |
| ROE % | 18.1% | 16.5% | -30.0% | -41.7% | -29.3% | -32.3% | -32.2% | -19.0% | -72.4% |
| ROCE % | - | -86.9% | -21.6% | -19.6% | -19.4% | -20.9% | -20.7% | -13.1% | -38.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | First Light Asset Management, LLC | 17.02% | 12.81M | $22.68M |
| 2 | Cdc Financial, Inc. | 9.42% | 7.09M | $12.55M |
| 3 | Palogic Value Management, LP | 6.54% | 4.92M | $8.71M |
| 4 | Impax Asset Management Group plc | 5.32% | 4.00M | $7.08M |
| 5 | Nepsis, Inc. | 3.95% | 2.98M | $5.27M |
| 6 | Vanguard Capital Management LLC | 3.95% | 2.97M | $5.26M |
| 7 | Blackrock Inc. | 2.44% | 1.84M | $3.25M |
| 8 | Jane Street Group, LLC | 1.38% | 1.04M | $1.84M |
| 9 | Dimensional Fund Advisors LP | 1.21% | 911.82K | $1.61M |
| 10 | Geode Capital Management, LLC | 1.18% | 891.36K | $1.58M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HCAT
HCAT Jan 2027 2.500 call (HCAT270115C00002500) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE1nTkM3aUdIZHdxTU5MWklfZXA5NFREWmtRXzVjWC16OHBTTlIxblFzYk15cHpiM2JtM1E4Rnd6b0FBbkZVMVdRTDQ5blB5UGFQTkVjU3VXOFkyWDdrRWVXZGRQZnJNZw?oc=5" target="_blank">HCAT Jan 2027 2.500 call (HCA…
Health Catalyst (HCAT) Stock Fair Value Falls As Analysts Cut Targets On Growth Risks - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOY0JlZ1FYNU1WeVo4ekNkRmhFb1ZHdUItUWxJRVBaSGlkZGpwcEVuZElFNHotVGlmQkdYOVBDNFJhRW43N09yVXpQY3lqZHk0Y2hnS19Udkx0NHNSdWF2TUc5TF9FVVJ1LUZxZmtsUEllYWZKQ0c4UlBTMkwyWnNUZ3pXZHZtUTV1RVVUND…
Data Analytics Stocks Q2 Results: Benchmarking Health Catalyst (NASDAQ:HCAT) - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxNODZyOUliU2t0b2dZLXp6SExjMW1VZlZLV3ZpbnVwY1dsYjQ4OEFWNDhaV2ZNc2U0ZW9JY243T0NmaHUtNGFFVFZpNDhXc1dXb2lBNXQxYU5IdGFVR1VCdEdGOHUyR0tETHB1T2pnY3RWTkl0TFNPVm9jUkxLWVJOdFBvTGl2V0JkWjBza2…
Health Catalyst (HCAT): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOeDdvMnd6bDZySE54UUZJZm5KVnh6ZlpuNkQteEsxMWY2aC0zMDRJQldfM2x4WkFFX0htWUxtTnpOeE1HQmI2bmRTOXNnU2N6YWloOFg2M2NhU2Q3RGFGQnpXcFVpQzBuOXBOenNiLXE1emdHbDVsVTk1MGZrR1VnbnA2M1BpX2VNNk1Lc3…
3 Reasons to Sell HCAT and 1 Stock to Buy Instead - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPTmlTci1ZamxLRlF5ckp1cHhXVllzc0gwSTRURk50TGVaV3lVSGw4OFN3akt2XzZwbWJrUGZFVlRRYmlwZ1p3dGdYQVpqRTROdlFza3hyeHNpWHcxVUhNZ2Y5OFZ3X1psRkxLOEJnUEVScVFUOVlvOXdRbktRZk1IMmhsWFJSY2s3WDM5ZU…
Health Catalyst (HCAT) Stock Trades Up, Here Is Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQcDkwM2JwNlFueTFBdDFLVHJ3Vk0zOVFTeDZiVm5MTUwxMXNkdE1BcW1vTUEtdDIyTms4M1J0V2lOQVlPTmpMQUhUMlAzX25tMkR5bWpQWnRDT2RXSG9oODRNRjV1Vm5jR0pCbVRRTm5jclpQOU1qb0RlS3dJRGlfbnB3TnNicDFucHd6V0…
HCAT — Frequently Asked Questions
What is the current share price of Health Catalyst, Inc. (HCAT)?
As of 2026-10-23 16:27 PDT, Health Catalyst, Inc. (HCAT) trades at $1.69 on NasdaqGS. Its 52-week range is $1.00 to $3.69.
What is the market capitalisation of HCAT?
Health Catalyst, Inc. (HCAT) has a market capitalisation of $127.18M on NasdaqGS.
What is the P/E ratio of HCAT?
HCAT trades at a trailing price-to-earnings (P/E) ratio of -0.46. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.32.
What is the return on equity (ROE) of HCAT?
HCAT has a return on equity (ROE) of -118.12%. Its return on capital employed (ROCE) is -38.94%.
Is HCAT a good stock to buy?
This page provides a data-driven analysis of Health Catalyst, Inc. (HCAT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.